Welcome to LookChem.com Sign In|Join Free

CAS

  • or
(3S,4R,5R)-3-[(R)-1-hydroxyethyl]-5-{(1R,2S,5R)-[2-isopropyl-5-methylcyclohexyl]oxy}-3,4-(isopropylidenedioxy)-4,5-dihydro-3H-furan-2-one is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1449306-99-3

Post Buying Request

1449306-99-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • (3S,4R,5R)-3-[(R)-1-hydroxyethyl]-5-{(1R,2S,5R)-[2-isopropyl-5-methylcyclohexyl]oxy}-3,4-(isopropylidenedioxy)-4,5-dihydro-3H-furan-2-one

    Cas No: 1449306-99-3

  • Need to discuss

  • No requirement

  • Adequate

  • ORCHID CHEMICAL SUPPLIES LTD
  • Contact Supplier

1449306-99-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1449306-99-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,4,9,3,0 and 6 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1449306-99:
(9*1)+(8*4)+(7*4)+(6*9)+(5*3)+(4*0)+(3*6)+(2*9)+(1*9)=183
183 % 10 = 3
So 1449306-99-3 is a valid CAS Registry Number.

1449306-99-3Relevant articles and documents

Synthesis of enantiomerically pure model compounds of the glucose-6-phosphate-T1-translocase inhibitors kodaistatins A-D. Inferences with regard to the stereostructure of the natural products

Wüster, Thomas,Kaczybura, Natasza,Brückner, Reinhard,Keller, Manfred

, p. 7785 - 7809 (2013/08/23)

The kodaistatins A and C (5a,b) inhibit a step in glucose-metabolism at ~100 nM concentrations. This makes them potential 'leads' in the therapy of diabetes. We elucidated the (S)-configuration of the side-chain stereocenter of kodaistatin A by ozonolysis/reduction. The 13C NMR shifts of kodaistatin A model cis-11 suggest that the diol moiety in the dihydroxycyclopentanone core of kodaistatin is trans-configured. This model was prepared from the Feringa lactone (21) and (S)-2-methylbutanal (27) in 23 steps (14 steps in the longest linear sequence). We employed the same strategy for the simplified kodaistatin A model iso-cis-12, which resulted from the same substrates in 11 steps (6 steps in the longest linear sequence). The cyclopentenone cores of both targets stemmed from a C4+C1 approach. The C4 components were masked 'tartaric ketones' (16a,b) and a masked 'tartaric aldehyde' (18), respectively. The C1 components were the lithium-derivatives of the side-chain bearing phosphonates 19 and 22, respectively. The desired acylation/deprotonation/Horner-Wadsworth- Emmons tandem reaction succeeded in a single operation with the 'tartaric aldehyde' 18 but required partly or exclusively additional operations when we incorporated the 'tartaric ketones' 16a or 16b, respectively. The 'tartaric ketones' 16a,b contained an α-siloxyethyl substituent. It is noteworthy that it had to be introduced by adding the benzyltrimethylammonium enolate of lactone 18 to acetaldehyde because the lithium enolate of this lactone fragmented by an acetone-releasing β-elimination.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1449306-99-3